The biology of perlecan and its bioactive modules

Extracellular Matrix: Pathobiology and Signaling

Volumn , Issue , 2012, Pages 171-184

  Willis, Chris D ^a   Schaefer, Liliana ^b   Iozzo, Renato V ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877700445     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (58)

1. Arikawa-Hirasawa, E., Watanabe, E., Takami, H., Hassell, J. R., and Yamada, Y. (1999). Perlecan is essential for cartilage and cephalic development. Nat Genet 23, 354-358.
2. Arikawa-Hirasawa, E., Wilcox, W. R., Le, A. H., et al. (2001a). Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat Genet 27, 431-434.
3. Arikawa-Hirasawa, E., Wilcox, W. R., and Yamada, Y. (2001b). Dyssegmental dysplasia, Silverman-Handmaker type: unexpected role of perlecan in cartilage development. Am J Med Genet 106, 254-257.
4. Aviezer, D., Iozzo, R. V., Noonan, D. M., and Yayon, A. (1997). Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol 17, 1938-1946.
5. Baker, A. B., Ettenson, D. S., Jonas, M., Nugent, M. A., Iozzo, R. V., and Edelman, E. R. (2008). Endothelial cells provide feedback control for vascular remodeling through a mechanosensitive autocrine TGF-b signaling pathway. Circ Res 103, 289-297.
6. Bix, G., Castello, R., Burrows, M., et al. (2006). Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 98, 1634-1646.
7. Bix, G., Fu, J., Gonzalez, E., et al. (2004). Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through the alpha2beta1 integrin. J Cell Biol 166, 97-109.
8. Bix, G., Iozzo, R. A., Woodall, B., et al. (2007). Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the alpha2beta1-integrin receptor. Blood 109, 3745-3748.
9. Bix, G., and Iozzo, R. V. (2005). Matrix revolutions: "tails" of basement-membrane components with angiostatic functions. Trends Cell Biol 15, 52-60.
10. Cailhier, J. F., Sirois, I., Raymond, M.-A., et al. (2008). Caspase-3 activation triggers extracellular release of cathepsin L and endorepellin proteolysis. J Biol Chem 283, 27220-27229.
11. Chang, J. W., Kang, U.-B., Kim, D. H., et al. (2008). Identification of circulating endorepellin LG3 fragment: potential use as a serological biomarker for breast cancer. Proteomics Clin Appl 2, 23-32.
12. Cohen, I. R., Grässel, S., Murdoch, A. D., and Iozzo, R. V. (1993). Structural characterization of the complete human perlecan gene and its promoter. Proc Natl Acad Sci U S A 90, 10404-10408.
13. Cohen, I. R., Murdoch, A. D., Naso, M. F., Marchetti, D., Berd, D., and Iozzo, R. V. (1994). Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res 54, 5771-5774.
14. Costell, M., Carmona, R., Gustafsson, E., González-Iriarte, M., Fassler, R., and Munoz-Chápuli, R. (2002). Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice. Circ Res 91, 158-164.
15. Datta, M. W., Hernandez, A. M., Schlicht, M. J., et al. (2006). Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway. Mol Cancer 5, 9.
16. Datta, S., and Kankel, D. R. (1992). l(1)trol and l(1)devl, loci affecting the development of the adult central nervous system in Drosophila melanogaster. Genetics 130, 523-537.
17. Dodge, G. R., Kovalszky, I., Hassell, J. R., and Iozzo, R. V. (1990). Transforming growth factor beta alters the expression of heparan sulfate proteoglycan in human colon carcinoma cells. J Biol Chem 265, 18023-18029.
18. Echaniz-Laguna, A., Rene, F., Marcel, C., et al. (2009). Electrophysiological studies in a mouse model of Schwartz-Jampel syndrome demonstrate muscle fiber hyperactivity of peripheral nerve origin. Muscle Nerve 40, 55-61.
19. Fuki, I., Iozzo, R. V., and Williams, K. J. (2000). Perlecan heparan sulfate proteoglycan. A novel receptor that mediates a distinct pathway for ligand catabolism. J Biol Chem 275, 25742-25750.
20. Gonzalez, E. M., Mongiat, M., Slater, S. J., Baffa, R., and Iozzo, R. V. (2003). A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth. J Biol Chem 278, 38113-38116.
21. Gonzalez, E. M., Reed, C. C., Bix, G., et al. (2005). BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J Biol Chem 280, 7080-7087.
22. Goyal, A., Pal, N., Concannon, M., et al. (2011). Endorepellin, the angiostatic module of perlecan, interacts with both the alpha2beta1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2). J Biol Chem 286, 25947-25962.
23. Iozzo, R. V. (1995). Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab Invest 73, 157-160.
24. Iozzo, R. V. (1998). Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67, 609-652.
25. Iozzo, R. V., and Cohen, I. (1993). Altered proteoglycan gene expression and the tumor stroma. Cell Mol Life Sci 49, 447-455.
26. Iozzo, R. V., Cohen, I. R., Grassel, S., and Murdoch, A. D. (1994). The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302, 625-639.
27. Iozzo, R. V., and Murdoch, A. D. (1996). Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J 10, 598-614.
28. Iozzo, R. V., Pillarisetti, J., Sharma, B., et al. (1997). Structural and functional characterization of the human perlecan gene promoter. Transcriptional activation by transforming factor-beta via a nuclear factor 1-binding element. J Biol Chem 272, 5219-5228.
29. Iozzo, R. V., and San Antonio, J. D. (2001). Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 108, 349-355.
30. Iozzo, R. V., Zoeller, J. J., and Nyström, A. (2009). Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol Cells 27, 503-513.
31. Kvist, A. J., Johnson, A. E., Mörgelin, M., et al. (2006). Chondroitin sulfate perlecan enhances collagen fibril formation. Implications for perlecan chondrodysplasias. J Biol Chem 281, 33127-33139.
32. Laplante, P., Raymond, M.-A., Labelle, A., Abe, J.-I., Iozzo, R. V., and Hebert, M.-J. (2006). Perlecan proteolysis induces alpha2beta1 integrin and src-family kinases dependent antiapoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation. J Biol Chem 281, 30383-30392.
33. Lindner, J. R., Hillman, P. R., Barrett, A. L., et al. (2007). The Drosophila perlecan gene trol regulates multiple signaling pathways in different developmental contexts. BMC Dev Biol 7, 121.
34. Marchisone, C., Del Grosso, F., Masiello, L., Prat, M., Santi, L., and Noonan, D. M. (2000). Phenotypic alterations in Kaposi's sarcoma cells by antisense reduction of perlecan. Pathol Oncol Res 6, 10-17.
35. Mathiak, M., Yenisey, C., Grant, D. S., Sharma, B., and Iozzo, R. V. (1997). A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells. Cancer Res 57, 2130-2136.
36. Mongiat, M., Fu, J., Oldershaw, R., Greenhalgh, R., Gown, A., and lozzo, R. V. (2003a). Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem 278, 17491-17499.
37. Mongiat, M., Otto, J., Oldershaw, R., Ferrer, F., Sato, J. D., and lozzo, R. V. (2001). Fibroblast growth factor-binding protein is a novel partner for perlecan protein core. J Biol Chem 276, 10263-10271.
38. Mongiat, M., Sweeney, S., San Antonio, J. D., Fu, J., and lozzo, R. V. (2003b). Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278, 4238-4249.
39. Mongiat, M., Taylor, K., Otto, J., et al. (2000). The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7. J Biol Chem 275, 7095-7100.
40. Murdoch, A. D., Liu, B., Schwarting, R., Tuan, R. S., and lozzo, R. V. (1994). Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain lll and by in situ hybridization. J Histochem Cytochem 42, 239-249.
41. Nugent, M. A., Nugent, H. M., lozzo, R. V., Sanchack, K., and Edelman, E. R. (2000). Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci U S A 97, 6722-6727.
42. Nyström, A., Shaik, Z. P., Gullberg, D., et al. (2009). Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity. Blood 7 74, 4897-4906.
43. Rogalski, T. M., Gilchrist, E. J., Mullen, G. P., and Moerman, D. G. (1995). Mutations in the unc-52 gene responsible for body wall muscle defects in adult Caenorhabditis elegans are located in alternatively spliced exons. Genetics 739, 159-169.
44. San Antonio, J. D., Zoeller, J. J., Habursky, K., et al. (2009). A key role for the integrin a2b1 in experimental and developmental angiogenesis. Am J Pathol 775, 1338-1347.
45. Sharma, B., Handler, M., Eichstetter, I., Whitelock, J., Nugent, M. A., and lozzo, R. V. (1998). Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin lnvest 702, 1599-1608.
46. Sharma, B., and lozzo, R. V. (1998). Transcriptional silencing of perlecan gene expression by interferon-gamma. J Biol Chem 273, 4642-4646.
47. Sher, I., Zisman-Rozen, S., Eliahu, L., et al. (2006). Targeting perlecan in human keratinocytes reveals novel roles for perlecan in epidermal formation. J Biol Chem 28 7, 5178-5187.
48. Smith, S. M., Whitelock, J. M., lozzo, R. V., Little, C. B., and Melrose, J. (2009). Topographical variation in the distribution of versican, aggrecan and perlecan in the foetal human spine reflects their diverse functional roles in spinal development. Histochem Cell Biol 732, 491-503.
49. Stum, M., Davoine, C. S., Vicart, S., et al. (2006). Spectrum of HSPG2 (perlecan) mutations in patients with Schwartz-Jampel syndrome. Hum Mutat 27, 1082-1091.
50. Whitelock, J. M., Graham, L. D., Melrose, J., Murdoch, A. D., lozzo, R. V., and Underwood, P. A. (1999). Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol 78, 163-178.
51. Whitelock, J. M., and lozzo, R. V. (2005). Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 705, 2745-2764.
52. Whitelock, J. M., Melrose, J., and lozzo, R. V. (2008). Diverse cell signaling events modulated by perlecan. Biochemistry 47, 11174-11183.
53. Whitelock, J. M., Murdoch, A. D., lozzo, R. V., and Underwood, P. A. (1996). The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin and heparanases. J Biol Chem 277, 10079-10086.
54. Woodall, B. P., Nyström, A., lozzo, R. A., et al. (2008). lntegrin a2b1 is the required receptor for endorepellin angiostatic activity. J Biol Chem 283, 2335-2343.
55. Xu, Z., Ichikawa, N., Kosaki, K., et al. (2010). Perlecan deficiency causes muscle hypertrophy, a decrease in myostatin expression, and changes in muscle fiber composition. Matrix Biol 29, 461-470.
56. Zoeller, J. J., and Iozzo, R. V. (2008). Proteomic profiling of endorepellin angiostatic activity on human endothelial cells. Proteome Sci 6, 7.
57. Zoeller, J. J., McQuillan, A., Whitelock, J., Ho, S.-Y., and Iozzo, R. V. (2008). A central function for perlecan in skeletal muscle and cardiovascular development. J Cell Biol 181, 381-394.
58. Zoeller, J. J., Whitelock, J., and Iozzo, R. V. (2009). Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biol 28, 284-291.